Unknown

Dataset Information

0

Volasertib preclinical activity in high-risk hepatoblastoma.

ABSTRACT: Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. In a chemical screen, we identified volasertib as an agent with in vitro activity, inhibiting hepatoblastoma cell growth while sparing normal hepatocytes. Volasertib targets PLK1 and prevents the progression of mitosis, resulting in eventual cell death. PLK1 is overexpressed in hepatoblastoma biopsies relative to normal liver tissue. As a potential therapeutic strategy, we tested the combination of volasertib and the relapse-related hepatoblastoma chemotherapeutic irinotecan. We found both in vitro and in vivo efficacy of this combination, which may merit further preclinical investigation and exploration for a clinical trial concept.

SUBMITTER: Kats D 

PROVIDER: S-EPMC6849653 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. In a chemical screen, we identified volasertib as an agent with <i>in vitro</i> activity, inhibiting hepatoblastoma cell growth while sparing normal hepatocytes. Volasertib targets PLK1 and prevents the progression of mitosis, resulting in eventual cell death. PLK1 is overexpressed in hepatoblastoma biopsies relative to normal liver tissue. As a potential therapeutic strategy, we  ...[more]

Similar Datasets

Genomics Volasertib preclinical activity in high-risk hepatoblastoma
| EGAS00001004827 | EGA
Unknown Hepatoblastoma: current knowledge and promises from preclinical studies.
| S-EPMC7063515 | biostudies-literature
Unknown Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells.
| S-EPMC7429182 | biostudies-literature
Unknown Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
| S-EPMC5137489 | biostudies-literature
Unknown Association of CMYC polymorphisms with hepatoblastoma risk
| S-EPMC8798278 | biostudies-literature
Unknown Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
| S-EPMC4241497 | biostudies-literature
Unknown Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
| S-EPMC5716199 | biostudies-literature
Unknown CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China.
| S-EPMC7708347 | biostudies-literature
Transcriptomics Genome-wide mapping of oncogenic pathways and genetic modifiers of chemotherapy using a high-risk hepatoblastoma genetic model
2023-06-22 | GSE193124 | GEO
Unknown Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
| S-EPMC5665173 | biostudies-literature